OrganiGram (OGI) reported a quarterly loss but beat revenue estimates, causing uncertainty.

From Nasdaq: 2025-05-12 19:15:00

OrganiGram (OGI) reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of a loss of $0.03. This represents an adjusted loss of $0.12 per share from a year ago. The company has surpassed EPS estimates only once in the last four quarters.

OrganiGram exceeded revenue expectations, reporting $45.69 million for the quarter ended March 2025, beating estimates by 8.09%. The stock has declined by 26.7% since the beginning of the year, while the S&P 500 fell by -3.8%. The company’s future performance will depend on management’s commentary and earnings outlook.

Investors are questioning the future of OrganiGram’s stock. The company’s earnings estimate revisions are unfavorable, resulting in a Zacks Rank #4 (Sell). The current consensus EPS estimate is -$0.02 for the coming quarter and -$0.16 for the fiscal year. The Medical – Products industry is currently ranked in the bottom 33% of Zacks industries.

TriSalus Life Sciences, Inc. (TLSI) is expected to report a quarterly loss of $0.20 per share, representing a year-over-year increase of +63%. Revenue is expected to be $9.26 million, up 43.4% from the previous year. The company has yet to release its results for the quarter ended March 2025.

For investors considering Organigram Global Inc. (OGI), it is crucial to monitor the company’s earnings outlook, estimate revisions, and industry performance. Zacks Investment Research provides tools and analysis to help investors make informed decisions. Download the free report on the 7 best stocks to buy for the next 30 days for more insights.



Read more at Nasdaq: OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)